Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically De
A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy ---- This patient also achieved 84.6% reduction in target lesion size, as previously reported by Gen…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.